Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Uterine Neoplasms: Tumors or cancer of the UTERUS.Smooth Muscle Tumor: A tumor composed of smooth muscle tissue, as opposed to leiomyoma, a tumor derived from smooth muscle.Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Vena Cava, Inferior: The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.Genital Neoplasms, Male: Tumor or cancer of the MALE GENITALIA.Retroperitoneal NeoplasmsMuscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Mesenchymoma: A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)Spermatic Cord: Either of a pair of tubular structures formed by DUCTUS DEFERENS; ARTERIES; VEINS; LYMPHATIC VESSELS; and nerves. The spermatic cord extends from the deep inguinal ring through the INGUINAL CANAL to the TESTIS in the SCROTUM.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Renal Veins: Short thick veins which return blood from the kidneys to the vena cava.Liposarcoma: A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)Skull Neoplasms: Neoplasms of the bony part of the skull.Jejunal Neoplasms: Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).Histiocytoma, Malignant Fibrous: The most commonly diagnosed soft tissue sarcoma. It is a neoplasm with a fibrohistiocytic appearance found chiefly in later adult life, with peak incidence in the 7th decade.

*  1 Million Study on Leiomyosarcoma Set to Begin
Leiomyosarcomas Have Varied Biologic and Clinical Features. Leiomyosarcoma (LMS) is a heterogeneous disease including seven ... Leiomyosarcoma Research. ---Collagen Deletion. ---Global Collaborative Study. ---Mir-17-92 Dysregulation. ---Mouse Model. --- ... New Therapeutic Targets in Leiomyosarcoma. Figure 1: Recurrent genetic alterations in the pathogenesis of.... Unlike in some of ... 1 Million Study on Leiomyosarcoma Set to Begin. August 8, 2016 - The Liddy Shriver Sarcoma Initiative is pleased to announce ...
*  Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma - Full Text View -...
Uterine Corpus Leiomyosarcoma Biological: Ipilimumab Other: Laboratory Biomarker Analysis Biological: Nivolumab Phase 2 ... Leiomyosarcoma. Neoplasms, Muscle Tissue. Neoplasms, Connective and Soft Tissue. Neoplasms by Histologic Type. Neoplasms. ... Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma. This study is ... Patients must have histologically or cytologically confirmed advanced leiomyosarcoma of the uterus (ULMS); advanced ULMS is ...
*  DMOZ - Health: Conditions and Diseases: Cancer: Musculoskeletal: Soft Tissue Sarcoma: Leiomyosarcoma
Leiomyosarcoma.info Provides medical information for patients and doctors, including a tutorial, treatment options, support and ... Non-profit entity whose stated aim is to advance treatment and research efforts for leiomyosarcoma patients. ...
*  A Rare Occurrence of Primary Hepatic Leiomyosarcoma Associated with Epstein Barr Virus Infection in an AIDs Patient
Hepatic leiomyosarcomas are unusual tumors. Most of them are metastatic leiomyosarcomas. Primary hepatic leiomyosarcoma is a ... and myxoid leiomyosarcoma, respectively. Type 4 or myxoid leiomyosarcoma has an aggressive growth pattern [14, 15]. ... followed by leiomyosarcoma (12%), fibrosarcoma (7%), and other sarcomas (44%) [4]. Most of the hepatic leiomyosarcomas are ... Myxoid leiomyosarcoma of the uterus. A report of six cases. American Journal of Surgical Pathology. 1982;6(7):589-598. [PubMed] ...
*  Case of the Week #237
The differential diagnosis includes leiomyosarcoma, symplastic leiomyoma and fibromatosis. Leiomyosarcomas have smooth muscle ... Both leiomyosarcomas and leiomyomas show some smooth muscle features by immunohistochemistry (smooth muscle actin or desmin ...
*  Central Role of CEMIP in Tumorigenesis and Its Potential as Therapeutic Target
uterine leiomyosarcoma. sarcoma. Located at 15q25.1. Related to uterine leiomyosarcoma. [1]. N/M: not mention; Ref.: reference. ... Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization. J ... is strong relationship between expression of CEMIP and tumourigenesis as it has been emphasised in uterine leiomyosarcomas, ...
*  Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus - Full Text View -...
... and it has been shown to decrease the size of leiomyosarcoma tumors in patients with leiomyosarcoma of the uterus that has ... Pathologically confirmed leiomyosarcoma of the uterus, completely resected, stage I, II, III or IV within 8 weeks of surgery to ... This is a pilot study of adjuvant therapy for patients with leiomyosarcoma of the uterus that has been completely removed by ... Leiomyosarcoma. Uterine Neoplasms. Neoplasms, Muscle Tissue. Neoplasms, Connective and Soft Tissue. Neoplasms by Histologic ...
*  Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy...
Histologically confirmed uterine leiomyosarcoma. *Persistent or recurrent disease that is refractory to curative or established ... No prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of uterine leiomyosarcoma within the past ... A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus. ... To determine if beta-III tubulin expression as measured by IHC predicts response to ixabepilone in women with leiomyosarcoma. ...
*  Re: [MOL] Leiomyosarcoma//Reply [02853]
Subject: [MOL] Leiomyosarcoma. My wife has been diagnosed with leiomyosarcoma of the tongue. Could you send me all the ...
*  A rare case of paratesticular leiomyosarcoma.
We present a case of paratesticular leiomyosarcoma in an 88-year-old man presenting with a left scrotal mass with ultra ... Paratesticular leiomyosarcomas are rare and can lead to significant morbidity and mortality, if inadequately diagnosed or ... Scrotal leiomyosarcoma is thought to arise from the dartos layer of the scrotum [7]. Like other sarcomas, leiomyosarcoma tends ... of spermatic cord tumours are leiomyosarcomas [5]. Around 110 cases of leiomyosarcoma of the spermatic cord have been reported ...
*  Stomach and Intestinal Cancer (Leiomyosarcoma) in Cats | petMD
... or leiomyosarcoma) is an uncommon, painful painful disease affects mostly older cats, though all breeds are equally predisposed ... Leiomyosarcoma of Stomach, Small and Large intestine in Cats. Leiomyosarcoma is an uncommon cancerous tumor, which, in this ...
*  Leiomyosarcoma | Roswell Park Comprehensive Cancer Center
A malignant (cancer) tumor of smooth muscle cells that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.. ...
*  Rare Cancer Support Forum • View forum - Leiomyosarcoma - LMS
Leiomyosarcoma - LMS. You do not have the required permissions to read topics within this forum. ...
*  I Have Leiomyosarcoma
A Leiomyosarcoma anonymous support group with information on di... ... Join friendly people sharing true stories in the I Have Leiomyosarcoma group. Find support forums, advice and chat with groups ... Leiomyosarcoma I was told I have leiomyosarcoma on the left kidney and liver the first of Mar.2011 As of yet I have not found a ... A Leiomyosarcoma anonymous support group with information on diagnosis, treatment, symptoms, along with personal stories and ...
*  Primary Pulmonary Leiomyosarcoma Treated with Chemotherapy and Surgery | OMICS International
Primary pulmonary leiomyosarcomas are a rare malignant tumor with generally poor prognosis. They pose important problems of ... Pulmonary sarcoma; Leiomyosarcoma; Computed tomography; Chemotherapy; Surgery. Introduction. Leiomyosarcomas are neoplasms of ... Pulmonary leiomyosarcoma is the most common pathological type. Leiomyosarcoma of the lungs, it may originate in the arteriolar ... Primary Pulmonary Leiomyosarcoma Treated with Chemotherapy and Surgery Ayadi-Kaddour A1*, Hamrouni R1, Fekih L2, Marghli A3 and ...
*  Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Its use in patients with leiomyosarcoma is. experimental. Up to 80 patients will take part in this study. All will be enrolled ... A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma. Trial ... 2. Histologically confirmed uterine leiomyosarcoma with disease limited to the uterus. (determined by surgical staging or ... A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma ...
*  Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment
Uterine sarcomas are composed of leiomyosarcoma, endometrial stromal sarcoma and carcinosarcoma. Among these, leiomyosarcoma is ... Fig.2a).2a). Gene sets associated with leiomyosarcoma and myogenic targets were enriched in subtype I (Fig. ​(Fig.2b),2b), ... Leiomyosarcoma. MAP K13. Mitogen-activated protein kinase 13. MYH11. Myosin-11. MYLK. Myosin light chain kinase. MYOCD. ... Uterine leiomyosarcoma metastatic to thyroid shown by 18F-FDG PET/CT imaging. Revista espanola de medicina nuclear e imagen ...
*  Leiomyosarcoma - Wikipedia
"Leiomyosarcoma". Hematology/oncology clinics of North America. "Basic info". www.leiomyosarcoma.info. LMS leiomyosarcoma. ... Leiomyosarcoma LMS leiomyosarcoma.info Comprehensive reference site for information on leiomyosarcoma National Leiomyosarcoma ... Uterine leiomyosarcomas come from the smooth muscle in the muscle layer of the uterus. Cutaneous leiomyosarcomas derive from ... "About Chemotherapy". www.leiomyosarcoma.info. LMS leiomyosarcoma. August 2002. Archived from the original on 2009-06-25. Abu- ...
*  JCDR - Prognosis, Leiomyosarcoma, Orbit
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
*  Perineal leiomyosarcoma and its surgical treatment in a heifer | Veterinary Record
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center's RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
*  Imaging of leiomyosarcoma of the inferior vena cava: comparison of 2 cases and review of the literature.
This study compares a 4-cm leiomyosarcoma of the inferior vena cava dis ... Leiomyosarcoma of the inferior vena cava is a rare tumour arising from the smooth muscle fibres of the media with a mean size ... Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is a very rare tumour (less than 1% of all malignant tumours)[1] but is ... Leiomyosarcoma of the inferior vena cava is a rare tumour arising from the smooth muscle fibres of the media with a mean size ...
*  Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS
... McClain KL, Leach CT, Jenson HB, et al.. Abstract ... EBV clonality of leiomyosarcomas was determined by Southern blot analysis with oligonucleotide probes for EBV terminal-repeat ... Two colonic leiomyosarcomas obtained from different sites at different times from one patient contained different episomal EBV ... In situ hybridization showed EBV genomes in all muscle cells of the five leiomyosarcomas and the two leiomyomas from the six ...

(1/527) Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma.

Distinction of malignant uterine leiomyosarcomas from benign leiomyomas by morphological criteria is not always possible. Leiomyosarcomas typically have complex cytogenetic abnormalities; in contrast, leiomyomas have simple or no cytogenetic abnormalities. To understand better the biological distinction(s) between these tumors, we analyzed two other potential markers of genomic instability, loss of heterozygosity (LOH) and microsatellite instability. We examined archival materials from 16 leiomyosarcomas and 13 benign leiomyomas by polymerase chain reaction for 26 microsatellite polymorphisms. Markers were selected based on previous reports of cytogenetic or molecular genetic abnormalities in leiomyosarcomas or leiomyomas and surveyed chromosomes 7, 9, 10, 11, 12, 14, 15, 16, 18, 21, and X. LOH for markers on chromosomes 15, 18, 21, and X was infrequent in leiomyosarcomas (1 of 6 tumors for each chromosome) and not observed for markers on chromosomes 7, 9, 11, 12, 14, or 16. Interestingly, 8 of 14 (57.2%) informative leiomyosarcomas had LOH for at least one marker on chromosome 10 and involved both chromosomal arms in 45.5% (5 of 11). In contrast to leiomyosarcomas, LOH for chromosome 10 was not found in 13 benign leiomyomas. Microsatellite instability was found infrequently in leiomyosarcomas and not detected in leiomyoma. Clinicopathological features (eg, atypia, necrosis, and clinical outcome) did not appear to correlate with LOH for chromosome 10. In contrast to other chromosomes studied, LOH on chromosome 10 was frequent in leiomyosarcomas and absent in benign leiomyomas.  (+info)

(2/527) Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice.

To study the role in AIDS pathogenesis of the human immunodeficiency virus type 1 (HIV-1) Tat protein, a transactivator of viral and cellular genes, we generated transgenic mice with a recombinant DNA containing BK virus (BKV) early region and the HIV-1 tat gene, directed by its own promoter-enhancer. DNA hybridization revealed that the transgene is stably maintained in all organs of transgenic mice as a tandem insertion in a number of copies ranging from 5 to 20 per cell. In addition, tat and BKV RNA were expressed in all tissues. Transgenic mice developed three types of lesions: 1) tumors, 2) hyperplastic and dysplastic lesions, and 3) non-neoplastic lesions. Tumors of different histotypes, such as lymphomas, adenocarcinomas of skin glands, leiomyosarcomas, skin squamous cell carcinomas, hepatomas, hepatocarcinomas, and cavernous liver hemangiomas, developed in 29% of transgenic animals. The majority of tumors were malignant, invasive, and producing metastases. Conversely, tumors of only two histotypes (lymphomas and adenocarcinomas of skin glands) appeared in control mice. Hyperplastic and dysplastic lesions were more frequent in transgenic than in control mice and involved the skin or its adnexes, the liver and the rectum, indicating multiple targets for the activity of the transgene. Pyelonephritis, frequently complicated with hydronephrosis, inflammatory eye lesions, and amyloid depositions represented the most frequent non-neoplastic lesions detected in transgenic mice. Many of the pathological findings observed in this animal model are comparable to similar lesions appearing in AIDS patients, suggesting a relevant role for Tat in the pathogenesis of such lesions during the course of AIDS.  (+info)

(3/527) Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma.

BACKGROUND: Calponin h1, a basic actin-binding protein capable of inhibiting smooth muscle contraction, is a constitutive element of smooth muscle cells. However, in leiomyosarcoma (a type of smooth muscle neoplasm of the uterus), reduced expression of calponin h1 is observed, as we have reported previously. In this study, we sought to assess the effects (in vitro and in vivo) of increasing calponin h1 expression in leiomyosarcoma cells. METHODS: A plasmid containing a human calponin h1 complementary DNA and a bacterial neomycin-resistance gene was transfected into the human leiomyosarcoma cell lines SKN and SK-LMS-1 by electroporation. Southern blotting, reverse transcription-polymerase chain reaction analysis, western blotting, and immunohistochemistry were used to confirm DNA transfer and expression of the calponin h1 protein in neomycin-resistant clones. We characterized the morphology of calponin h1-transfected cells, and we evaluated their proliferative activity and tumorigenicity by use of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay, an anchorage-independent growth assay, and a nude mouse tumorigenicity assay. RESULTS: The morphology of calponin h1-transfected cells in culture resembled that of cultured normal myometrial smooth muscle cells. With SK-LMS-1 cells, proliferation of calponin h1-transfection cells was reduced to 69% of control; with SKN cells, calponin h1 transfection reduced proliferation to 70% of control. In assays of anchorage-independent growth and in vivo tumorigenicity, both growth and tumorigenicity were statistically significantly reduced in calponin h1-transfected leiomyosarcoma cells. CONCLUSIONS: Calponin h1 may function as a tumor suppressor in leiomyosarcoma. Clinically, transfer of a calponin h1 complementary DNA into poorly differentiated leiomyosarcoma cells may be of potential therapeutic value through induction of a normal, differentiated cellular phenotype.  (+info)

(4/527) Cerebral metastasis of a uterine leiomyosarcoma--case report.

A 38-year-old female presented with sudden neurological deterioration 6 years after an operation and chemotherapy for uterine leiomyosarcoma. An extremely rare metastasis of the uterine leiomyosarcoma to the brain was identified and totally resected. Whole brain irradiation (50 Gy) was given. A recurrence of the metastasis was resected 10 weeks later. She ultimately died of a second recurrence. Aggressive surgical management of cerebral metastasis of uterine leiomyosarcoma may achieve an improved outcome.  (+info)

(5/527) Leiomyosarcoma of the esophagus in a patient with chagasic megaesophagus: case report and literature review.

Leiomyosarcoma constitutes approximately 0.5% of the malignant neoplasias of the esophagus and its association with megaesophagus has not been described. We report on a case of a woman with dysphagia that was slowly progressive from the age of 19 due to chagasic megaesophagus. The woman was subjected to cardiomyotomy at the age of 49. She presented a rapid worsening of the dysphagia due to leiomyosarcoma at the age of 61, and was subjected to subtotal esophagectomy with cervical esophagogastroplasty. She developed pulmonary and hepatic metastases 14 months after surgery and died six months later.  (+info)

(6/527) "Mesenchymal tumor" or "decidual-like reaction"?

For more than 40 yr, an unusual urinary bladder lesion has been known to occur in certain strains of mice, but no consensus has been obtained regarding its etiology, pathogenesis, biology, or classification. The lesion was first assumed to be epithelial and non-neoplastic, then it was called a smooth muscle cell tumor or leiomyosarcoma because of ultrastructural characteristics for smooth muscle cells. Later, the nonspecific term "mesenchymal tumor" was introduced due to histomorphologic differences from all smooth muscle tumors known. Recently, a proposal was made to name it "decidual-like reaction" because of the histomorphologic similarity to the rare spontaneous decidual reaction in the uterus of aging mice. Both lesions are characterized by spindle and large pleomorphic epithelioid cells with large bizarre nuclei; these characteristics mimic anaplasia of malignant tumors and led pathologists to assume a neoplastic nature. The decidual hypothesis is supported by the regular presence of nuclear progesterone receptors, the occasional occurrence of eosinophilic cytoplasmic granules, the rare finding of cells morphologically resembling granulated metrial gland cells (all also observed in the uterine decidual reaction), and the reproducibility through long-term feeding of combinations of estrogens and progestogens. It appears that the new decidual hypothesis can explain many detailed facets of the lesion, with the exception of the reported smooth muscle cell characteristics. The controversy of "mesenchymal tumor versus decidual-like reaction" should be resolved soon, not only as a scientific issue, but also because of consequences for risk assessment.  (+info)

(7/527) Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group.

Soft-tissue tumors have proved to be a fruitful area for the identification of reproducible cytogenetic aberrations, especially among pediatric round-cell sarcomas and lipomatous tumors. Thus far, however, data regarding sarcomas of monomorphic spindle cell type have been limited and somewhat disappointing, with the notable exception of synovial sarcoma. As part of an ongoing international collaborative study, 130 karyotyped spindle-cell sarcomas were reviewed and classified histologically, without knowledge of the clinical and karyotypic data, with the aim of identifying objective correlations between morphology, karyotype, and clinical parameters. Clonal chromosomal abnormalities were identified in 82 cases studied (63%), but only in the group of synovial sarcomas was there clear correlation between the cytogenetic findings, in the form of a consistent t(X;18)(p11;q11), and morphology. Among leiomyosarcomas (41 cases) and malignant peripheral nerve sheath tumors (MPNSTs; 27 cases) as well as in individual examples of rarer entities, there was a general tendency for karyotypic complexity associated with frequent loss or rearrangement of chromosome arms 1p, 10p, 11q, 12q, 17p, and 22q. Rearrangements of 17q (the region of the NF1 gene) were seen in 9/27 (33%) of MPNSTs. Among nine cases of solitary fibrous tumor (in which previous cytogenetic data are very limited) no consistent aberrations were identified. We conclude that, with the exception of synovial sarcoma, most spindle-cell sarcomas share with pleomorphic sarcomas the tendency for karyotypic complexity. There was no indication (in most of these lesions) that detectable cytogenetic aberrations could either facilitate their diagnosis or help to determine prognosis. There is a clear need to further study and understand the significance of multiple chromosomal abnormalities in this group of mesenchymal neoplasms with the particular goal of determining their role in the process of tumor development.  (+info)

(8/527) Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.

We examined bcl-2 expression as well as p53 expression and mutation in human uterine smooth muscle tumours to determine the influence of bcl-2 expression on prognosis in patients with uterine leiomyosarcomas. bcl-2 protein was expressed in nearly all benign smooth muscle tumours but in only 57% of leiomyosarcomas. Benign smooth muscle tumours were usually negative for p53 protein, but 16 out of 21 (76%) leiomyosarcomas were positive. A p53 gene mutation was detected in nine of the 16 leiomyosarcomas that showed p53-positive staining. A significant positive correlation was observed between p53 mutation and p53 expression, between the number of mitoses and the Ki-67 labelling index, and between clinical stage and p53 mutation. A significant negative correlation was observed between bcl-2 expression and p53 mutation, and between bcl-2 expression and p53 overexpression. Univariate survival analysis revealed that bcl-2 expression, p53 mutation and clinical stage (stage 1 vs stages 2-4) all showed a significant correlation with prognosis. In a multivariate stepwise regression analysis, positive bcl-2 expression and stage 1 disease were the independent predictors of a favourable prognosis. Our results suggest that bcl-2 is frequently expressed in human uterine smooth muscle tumours, and that its expression may correlate with a favourable prognosis in patients with uterine leiomyosarcoma.  (+info)